Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

Summary

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics (PD), immunogenicity, and efficacy of subcutaneous (SC) ALXN1830 in adults with generalized myasthenia gravis (gMG).

Timeline

Start

2022-01-01

Primary completion

2023-01-31

Completion

2024-01-31

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to terminate program”

Drugs

Indications